Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HOECHST-ROUSSEL’s SECOND GENERATION ALZHEIMER’s DRUG HP 749

Executive Summary

HOECHST-ROUSSEL's SECOND GENERATION ALZHEIMER's DRUG HP 749 entered Phase I trials in mid-September, the company's Neurosciences Group Director Richard Allen, PhD, reported at an Oct. 10 "University Day" conference sponsored by parent firm Hoechst-Celanese in Warren, New Jersey. To date, patients in the study have received three doses of the agent without evidence of major toxicity. The company is planning a number of presentations on the drug at the annual meeting of the Society of Neuroscience in St. Louis, Missouri Oct. 28-Nov. 2. Hoechst-Roussel Pharmaceutical Inc. is calling the cholinergic/adrenergic compound a second generation Alzheimer's drug because it treats the major cause of the disease, acetylcholine deficiency, as well as other neurotransmitter deficiencies found in Alzheimer's patients. In preclinical trials, HP 749 was found to amplify the signals of cholinergic neurons and to increase the release of norepinephrine in the brain. HP 749 is Hoechst-Roussel's third Alzheimer's drug in clinicals after velnacrine maleate (Mentane) and suronacrine. Noting that Hoechst-Roussel currently has two other Alzheimer's drugs ready to enter the clinic and three more not far behind, Allen said: "We are in this for the long run [and] it is our objective to be the Alzheimer's company." Hoechst-Roussel's lead Alzheimer's compound, velnacrine, entered Phase III trials this summer and will be tested nationwide in 400 patients with early to middle-stage Alzheimer's disease. Those patients are receiving doses of 150-225 mg per day. Results of Phase II trials presented at the conference in 200 patients treated for 15 weeks with velnacrine showed that 40-50% of the patients experienced some response to the drug. Patients were dosed three times daily with either placebo or velnacrine for a total daily dose of 30 mg, 75 mg, 150 mg, or 225 mg. The major side effect of velnacrine treatment was liver toxicity. However, Allen maintained that in preclinical testing, overall "acute toxicity of velnacrine is anywhere from four to five times less than [Warner-Lambert's Cognex] tacrine [and that] velnacrine is clearly less toxic to liver cells than tacrine." Warner-Lambert filed an NDA for tacrine on June 4 ("The Pink Sheet" June 18, T&G-17). Allen noted that as with tacrine, "all patients do not respond [to velnacrine]." HP 749's increase of norepinepherine release, in addition to its colinergic enhancement, "is a key element in establishing that this compound should work in Alzheimer's patients beyond that subset of patients that velnacrine works in," Allen said. He added that the company feels "very certain [that HP 749] is going to be useful in patients with more advanced Alzheimer's." Allen also noted that velnacrine and HP 749 may act synergistically but that Hoechst-Roussel is currently testing them only as single agents. Hoechst-Roussel's third Alzheimer's compound, suronacrine, is currently in Phase II, but reportedly shows no clear efficacy advantage over the other Alzheimer's drugs in development.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel